Across TCGA pan-cancer cohorts, LIME1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LIME1 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LIME1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LIME1 expression acts as an unfavorable survival marker.

BLCA and ACC are the cancer types where LIME1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.174	0.720	<.001	24	view →
ACC	OS	Median	All	0.113	0.822	<.001	21	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LIME1 tumor-vs-normal RNA expression · all LIME1 data types